| Bioactivity | Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models[1][2]. |
| In Vivo | Taragarestrant (D-0502) exhibits superior PK profiles suitable for clinical development[1]. |
| Name | Taragarestrant meglumine |
| CAS | 2446618-18-2 |
| Formula | C32H42Cl2FN3O7 |
| Molar Mass | 670.60 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Lin WY, et, al. Abstract 5776: Pharmacologic and PK/PD study of D-0502: An orally bioavailable SERD with potent antitumor activity in ER-positive breast cancer cell lines and xenograft models. 2018 Jul 1;78(13):5776. [2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical. |
Taragarestrant meglumine
CAS: 2446618-18-2 F: C32H42Cl2FN3O7 W: 670.60
Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarest
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.